Dianthus Therapeutics’ (DNTH) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a report issued on Wednesday morning,Benzinga reports. They currently have a $40.00 price objective on the stock. Several other brokerages also recently weighed in on DNTH. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in […]
HC Wainwright reaffirmed their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a report issued on Wednesday morning,Benzinga reports. They currently have a $40.00 price objective on the stock. Several other brokerages also recently weighed in on DNTH. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in […]
